MarketInOut Stock Screener Log In | Sign Up

Damora Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Damora Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,326.7 mln
Float48.12 mln
Earnings Date10/30/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

46.89
Transformational upside

Relative Strength

96 / 100
Top performer

ROE

-103
Deeply negative

ROA

-96.34
Deeply negative

Business Description

Founded in 2011 and based in Waltham, Massachusetts, Damora Therapeutics Inc. is a drug development company working on new treatments for blood disorders across Denmark and North America. Its main focus is a group of antibody-based medicines designed to target a specific genetic mutation linked to certain blood cancers, with the goal of helping a broad range of patients affected by this condition. The company is also advancing a small molecule drug aimed at treating acute myeloid leukemia.

Key Fundamentals

EPS-0.25
ROE-103
ROIC-652
ROA-96.34
EBITDA, mln-262
EV / EBITDA-3.43
EV / EBIT-3.43

Quote Details

Last 21.49
Change -0.52 (-2.36%)
Open 21.95
Volume 339,515
Turnover 7,296,178
Average Volume 462,288

Financial Ratios

Leverage Ratio1.05
Current Ratio19.73
Price / Book3.44
Price / Tangible Book3.44

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price46.89
Short Ratio6.65
Short % of Float9.74

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 1.9% 79 / 100   
1 Month 6.23% 87 / 100   
2 Months -27% 18 / 100   
6 Months -15.26% 30 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog